Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Tebotelimab (previously known as MGD013) is an investigational, bispecific DART® molecule designed to independently or coordinately block PD-1 and LAG-3 checkpoint molecules to sustain or restore the function of exhausted T cells for the treatment of cancer. Monoclonal antibodies that target the immune checkpoints Lymphocyte-activation gene 3 (LAG-3) and PD-1 may have enhanced clinical activity when given in combination. Tebotelimab has been engineered to bind PD-1 and LAG-3 concomitantly or independently and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function.
Tebotelimab was being studied in combination with enoblituzumab (an investigational monoclonal antibody that targets B7-H3) in patients with squamous cell carcinoma of the head and neck who are PD-L1 negative. As of July 8, 2022, this study was closed for safety reasons. Please see press release.
Zai Lab has development and commercialization rights in Greater China. MacroGenics retains full development and commercialization rights in all other territories.
Relevant Publications and Presentations can be found at https://macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.